Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer

Pere Puig, Nadina Erill, Marta Terricabras, Isaac Subirana, Judit González-García, Adrià Asensi-Puig, Michael J. Donovan, Lourdes Mengual, M. Teresa Agulló-Ortuño, Mireia Olivan, Antonio Alcaraz, José A. López-Martín, Inés De Torres, José Luis Rodríguez-Peralto, Alfredo Rodríguez-Antolín, Juan Morote, Víctor González-Rumayor

Research output: Contribution to journalArticleResearch

Abstract

© 2019 The Author(s). Objectives: To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. Results: The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression.
Original languageEnglish
Article number68
JournalBMC Research Notes
Volume12
DOIs
Publication statusPublished - 30 Jan 2019

Keywords

  • Active β-catenin
  • HLA class1
  • Prostate cancer
  • Systems pathology
  • Wnt/β-catenin pathway

Fingerprint Dive into the research topics of 'Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer'. Together they form a unique fingerprint.

Cite this